| Literature DB >> 32587832 |
Abstract
Human Cytomegalovirus (HCMV) is a highly prevalent herpesvirus, persistently infecting between 30 and 100% of the population, depending on socio-economic status (Fields et al., 2013). HCMV remains an important clinical pathogen accounting for more than 60% of complications associated with solid organ transplant patients (Kotton, 2013; Kowalsky et al., 2013; Bruminhent and Razonable, 2014). It is also the leading cause of infectious congenital birth defects and has been linked to chronic inflammation and immune aging (Ballard et al., 1979; Griffith et al., 2016; Jergovic et al., 2019). There is currently no effective vaccine and HCMV antivirals have significant side effects. As current antivirals target viral genes, the virus can develop resistance, reducing drug efficacy. There is therefore an urgent need for new antiviral agents that are effective against HCMV, have better toxicity profiles and are less vulnerable to the emergence of resistant strains. Targeting of host factors that are critical to virus replication is a potential strategy for the development of novel antivirals that circumvent the development of viral resistance. Systematic high throughput approaches provide powerful methods for the identification of novel host-virus interactions. As well as contributing to our basic understanding of virus and cell biology, such studies provide potential targets for the development of novel antiviral agents. High-throughput studies, such as RNA sequencing, proteomics, and RNA interference screens, are useful tools to identify HCMV-induced global changes in host mRNA and protein expression levels and host factors important for virus replication. Here, we summarize new findings on HCMV lytic infection from high-throughput studies since 2014 and how screening approaches have evolved.Entities:
Keywords: HTS; RNAi; high-throughput; human cytomegalovirus; siRNA screen
Mesh:
Substances:
Year: 2020 PMID: 32587832 PMCID: PMC7298070 DOI: 10.3389/fcimb.2020.00280
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Summary of high-throughput studies.
| RNA-seq | Batra et al. ( | Affymetrix microarrays; poly-A selected RNA-seq; TAIL-seq | NPCs, HFFs, Ecs | TB40/E and Towne | HCMV mRNA expression pattern | Over 2,000 altered host RNA splicing events in infected HFFs and NPCs |
| Proteomics | Weekes et al. ( | TMT proteomics of 1,184 surface proteins and 7,491 cellular proteins | HFFFs (HFFs) | Merlin | HCMV protein expression profile | Not specified |
| Jean Beltran et al. ( | Subcellular fractionation, TMT-based and label-free mass spectrometry and confocal microscopy | HFFs | AD169-GFP | GFP expression from the virus | 796 proteins downregulated and 593 upregulated up to 96 HPI; 374 proteins showed translocation upon infection | |
| Arend et al. ( | Multiplexed kinase inhibitor bead-mass spectrometry (MIB-MS) quantitatively measure perturbations in 244 cellular kinases | MRC-5 | AD169 and TB40/E | Infection not measured | 53 kinases upregulated and 51 downregulated at multiple timepoints post-infection | |
| Nightingale et al. ( | TMT proteomics with proteasomal (MG132) and lysosomal (leupeptin) inhibitors; SILAC; RNA-seq | Immortalized HFFs (HFFF-TERTs) | Merlin | HCMV protein expression profile | 131 proteins were rescued by MG132 and 28 proteins by leupeptin within 24 h of infection | |
| Jean Beltran et al. ( | Targeted mass spectrometry against peroxisome proteins | HFFs | AD169 | Viral protein expression profile of IE1, pUL26 and pp65 | 52 peroxisome proteins showed increased expression from 24 HPI | |
| siRNA screens | Polachek et al. ( | An siRNA library, in a pool of 4 siRNAs, targeting 789 human kinases and phosphatases | HFFs | AD169 | Immunoflurescencely labeling pp28 | 26 proviral and 25 antiviral hits |
| Lin et al. ( | An siRNA library, in a pool of 4 siRNAs, targeting 140 membrane trafficking genes and 20 other selected genes | NHDF (HFFs) | TB40/E-GFP | SV40 promoter driven GFP expression from the virus | Not specified | |
| McCormick et al. ( | An siRNA library, in a pool of 4 siRNAs, targeting 156 host genes | NHDF (HFFs) | TB40/E-GFP | SV40 promoter driven GFP expression from the virus | 11 proviral and 31 antiviral hits from the virus production screen | |
| Lee et al. ( | An siRNA library, in a pool of 4 siRNAs, targeting 6,881 host genes with high therapeutic potential | NHDF (HFFs) | TB40/E-GFP | SV40 promoter driven GFP expression from the virus | 47 proviral and 68 antiviral hits | |
| Song et al. ( | An siRNA library, in a pool of 4 siRNAs, targeting 687 host genes involved in cellular RNA processing | HFFs | Toledo | RT-qPCR of IE1, UL44, UL99 at 48 HPI | 36 proviral genes based on UL99 expression | |
| shRNA screens | van de Weijer et al. ( | A high-coverage shRNA library of around 55,000 sequences (30 shRNAs per gene) | U937 | N/A; Cells expressing HCMV US11 proteins | Cells engineered to express chimeric HLA-A2 molecules with eGFP and Myc tags; cell sorting by FACS | Not specified; top 100 enriched sgRNAs/genes from both screens shown |
| CRISPR screens | van de Weijer et al. ( | A CRISPR library of 112 sgRNAs targeting 36 known human E2 enzymes | U937 | N/A; Cells expressing HCMV US2 proteins | Cells engineered to express eGFP-HLA-A2 molecules; cell sorting by FACS | Knockout of 2 genes showed rescue expression of eGFP-HLA-A2 and knockout of 1 gene showed further downregulation of eGFP-HLA-A2 |
| Wu et al. ( | A human genome-wide GeCKO library targeting 19,050 human genes with over 120,000 sgRNAs | HFFs | AD169 with UL131A insertion and Merlin with UL128 nonsense mutation | Sequence analysis of sgRNA enrichment in surviving cells | Not specified; top 10 enriched sgRNAs shown | |
| Xiaofei et al. ( | A human genome-wide GeCKO library targeting 19,050 human genes with over 120,000 sgRNAs | ARPE-19, HEL | TB40/E and AD169 | Sequence analysis of sgRNA enrichment in surviving cells | 312 candidates (≥3 sgRNAs, each with ≥20 reads) in ARPE-19 screen | |
| miRNA screens | Pavelin et al. ( | RISC-IP using an AGO2 specific antibody | NHDF (HFFs) | AD169 and TR | N/A | 686 transcripts were enriched over 2-fold in AD169-infected cells; 442 transcripts enriched in TR-infected cells |
| Kim et al. ( | AGO-CLIP-seq using a pan-AGO antibody | HFFs | TowneLONG | N/A | 3,909 HTVs |
TMT, tandem mass tag; RISC-IP, RNA-induced silencing complex immunoprecipitation.
NPCs, neural progenitor cells; HFFs, human foreskin fibroblasts; ECs, endothelial cells; HFFFs, human fetal foreskin fibroblast; HFFF-TERTs, HFFF immortalized with human telomerase; NHDF, normal human dermal fibroblast; HEL, human embryonic lung fibroblast.
HTVs, human targets of the viral miRNAs.
N/A, not applicable.
Figure 1Host factors identified in high-throughput studies and their role in HCMV infection. The life cycle of HCMV is summarized in the figure and candidates identified in each type of high-throughput studies were shown in their approximate functional location. Candidates identified in each type of high-throughput studies are in: red (RNA-seq), blue (proteomics), green (siRNA), purple (shRNA), brown (CRISPR), pink (miRNA).